Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Avalo Therapeutics (NASDAQ:AVTX) from a sell rating to a hold rating in a report issued on Sunday.

Other equities analysts have also issued research reports about the company. Leerink Partners started coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Citizens Jmp cut their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Wedbush reduced their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Piper Sandler reiterated an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Finally, HC Wainwright dropped their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $45.10.

Avalo Therapeutics Stock Performance

Shares of NASDAQ:AVTX opened at $19.71 on Friday. Avalo Therapeutics has a one year low of $8.41 and a one year high of $24.27. The stock has a fifty day moving average of $18.10 and a 200-day moving average of $16.49. The company has a market capitalization of $1.06 billion, a PE ratio of -4.51 and a beta of 0.80.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, research analysts forecast that Avalo Therapeutics will post -2.59 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Caligan Partners LP purchased a new stake in shares of Avalo Therapeutics in the third quarter worth approximately $10,592,000. Balyasny Asset Management L.P. purchased a new position in Avalo Therapeutics during the third quarter valued at approximately $10,390,000. Vanguard Group Inc. increased its stake in Avalo Therapeutics by 314.9% in the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after buying an additional 525,696 shares during the period. Millennium Management LLC increased its stake in Avalo Therapeutics by 380.2% in the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock valued at $11,985,000 after buying an additional 522,548 shares during the period. Finally, Seven Fleet Capital Management LP lifted its position in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after buying an additional 510,540 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.